News & Information

We post fresh news as it happens. Please check back periodically for updates.

Tivorsan Pharmaceuticals Granted FDA Orphan Drug Designation for Human Recombinant Biglycan in the Treatment of Duchenne Muscular Dystrophy

August 16th, 2016

PROVIDENCE, R.I.–(BUSINESS WIRE)–Tivorsan Pharmaceuticals, Inc., a biotechnology company that is pioneering a novel approach to treating all forms of Duchenne Muscular Dystrophy (DMD) and other serious, debilitating neuromuscular disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its lead investigational drug, human recombinant Biglycan, for the treatment […]

Read More

Tivorsan Pharmaceuticals closes private placement funds to support R&D of Biglycan for Duchenne Muscular Dystrophy

February 9th, 2016

Providence, RI, February 5, 2016 – Tivorsan Pharmaceuticals, Inc., a biotechnology company that is pioneering a novel approach to treating all forms of Duchenne Muscular Dystrophy (DMD) and other serious, debilitating neuromuscular disorders, today announced that it has raised approximately $1.8 million in private financing from a leading institutional investor, as well as other existing […]

Read More

Tivorsan Pharmaceuticals Names Business Leader James E. Connolly as CEO and Board Member

August 21st, 2015

Read the entire press release

Read More

Tivorsan Pharmaceuticals to Present at Biotech Showcase™ 2015 on Monday, January 12

January 8th, 2015

Providence, R.I., January 8, 2015 (BUSINESS WIRE) – Tivorsan Pharmaceuticals, Inc. today announced that Justin Fallon, PhD – Corporate Director, Founding Scientist and Brown University Professor – will present at next week’s Biotech Showcase™2015 in San Francisco, CA. Dr. Fallon will provide a company overview as well as the scientific rationale behind recombinant biglycan (TVN-102) […]

Read More

Tivorsan Pharmaceuticals Achieves Key Development Milestones under its Parent Project Muscular Dystrophy and Muscular Dystrophy Association Awards

January 7th, 2015

Jan. 7, 2015 Read the entire press release

Read More

Investment group Ocean State Angels bets on Brown-based biotech company

September 27th, 2013

Sep. 27, 2013 Read the entire press release

Read More

Biglycan in Synapse Stability of Motor Neurons

February 21st, 2012

PROVIDENCE, R.I. [Brown University] February 14, 2012 — A protein that has shown early promise in preventing the loss of muscle function in mouse models of Duchenne muscular dystrophy, has been found in a new study to be a key player in the process of joining nerves to muscles. The protein biglycan needs to be […]

Read More

MDA Awards $1 Million To Tivorsan Pharmaceuticals For Accelerating Pivotal Pre-clinical Work On Tvn-102 As A Potential Muscular Dystrophy Treatment

January 26th, 2012

NEWS from MDA: Jan. 5, 2012 Read the entire press release

Read More

DMD research nears clinical trials

December 7th, 2011

Providence Business News, Dec 5, 2011 DMD research nears clinical trials Read the entire article.

Read More

National Institutes of Health Awards Dr. Justin Fallon and Brown University $1.33M+ to Advance Biglycan to Clinic for Duchenne Muscular Dystrophy

October 27th, 2011

Funding Supplements Tivorsan Pharmaceuticals’ Commercialization Efforts of Biglycan as Novel Disease-Modifying Therapeutic PROVIDENCE, R.I.–(BUSINESS WIRE)– Tivorsan Pharmaceuticals announced today that its academic collaborators – Professor Fallon and his research group at Brown University – have received a generous award from the National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health […]

Read More